GleamWall
中文EN

ESLA Estrella Immunopharma, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1844417 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.7%
TTM EPS YoY20.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-484.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets936.1%
Debt / equity—
Current ratio0.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-143.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-06-30
Income statement
Revenue——
R&D expense$10.25M$4.11M
SG&A expense$2.81M$3.20M
Operating income-$13.06M-$7.31M
Pretax income-$13.06M-$7.31M
Income tax$838$1,625
Net income-$13.06M-$7.31M
EPS (basic)-0.35-0.27
EPS (diluted)-0.35-0.27
Weighted avg. shares (diluted)36.82M27.10M
Banking
Deposits$1.50M$1.50M
Balance sheet
Cash & equivalents$1.38M$4.17M
Current assets$1.68M$4.45M
Total assets$3.18M$4.45M
Current liabilities$13.54M$180,701
Total liabilities$13.54M$180,701
Shareholders' equity-$10.37M$4.27M
Shares outstanding37.97M36.61M
Cash flow statement
Operating cash flow-$1.79M-$16.07M
Investing cash flow—$4.96M
Financing cash flow$2.25M$12.79M
Stock-based compensation$618,974$1.19M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.